Zhang Yuyang, Kou Haiming, Cheng Zhipeng, Lu Xuan, Hu Yu, Tang Liang V
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Dadao, Wuhan, China.
Front Med (Lausanne). 2025 Oct 23;12:1666601. doi: 10.3389/fmed.2025.1666601. eCollection 2025.
Natural killer/T-cell lymphoma (NKTL) is a rare disease that shows suboptimal responses to existing therapies. This study reports the efficacy of the P3-GemOx regimen compared to the traditional PP-GemOx regimen in advanced NKTL.
Eleven patients received the P3-GemOx regimen [mitoxantrone hydrochloride liposome (Plm60) combined with PP-GemOx (anti-PD-1 antibody, pegaspargase, gemcitabine, and oxaliplatin)] every 3-4 weeks, with a median of 3 cycles (range: 1-4). Another eleven patients received the PP-GemOx regimen every 3-4 weeks, with a median of 4 cycles (range: 2-6). Treatment response was assessed using 18F-FDG-PET with CT or MRI.
All patients treated with P3-GemOx responded, with nine achieving complete remission (CR) and two partial remission (PR), yielding an overall response rate (ORR) of 100%. Seven of these patients underwent hematopoietic stem cell transplantation (HSCT). In the PP-GemOx group, the ORR was 63.6%, and no patients underwent HSCT. All adverse events were manageable and resolved.
The P3-GemOx regimen demonstrates superior efficacy over the PP-GemOx regimen in advanced NKTL.
自然杀伤/T细胞淋巴瘤（NKTL）是一种罕见疾病，对现有疗法反应欠佳。本研究报告了P3-GemOx方案与传统PP-GemOx方案相比，在晚期NKTL中的疗效。
11例患者每3 - 4周接受一次P3-GemOx方案[盐酸米托蒽醌脂质体（Plm60）联合PP-GemOx（抗PD-1抗体、培门冬酶、吉西他滨和奥沙利铂）]，中位疗程为3个周期（范围：1 - 4个周期）。另外11例患者每3 - 4周接受一次PP-GemOx方案，中位疗程为4个周期（范围：2 - 6个周期）。使用18F-FDG-PET联合CT或MRI评估治疗反应。
所有接受P3-GemOx方案治疗的患者均有反应，9例达到完全缓解（CR），2例部分缓解（PR），总缓解率（ORR）为100%。其中7例患者接受了造血干细胞移植（HSCT）。在PP-GemOx组中，ORR为63.6%，且无患者接受HSCT。所有不良事件均可控制并得到解决。
在晚期NKTL中，P3-GemOx方案显示出优于PP-GemOx方案的疗效。
